Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

RHEI Pharma Options China Rights for Invisicare

publication date: Feb 5, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

RHEI Pharmaceuticals NV of Belgium has optioned the China rights for Invisicare from Skinvisible, Inc. Invisicare is a patented polymer delivery system, designed to be combined with topical drug products, which extends the time that active pharmaceutical ingredients remain on the skin, resisting both wash off and perspiration. RHEI will seek SFDA approval for the product. Terms of the agreement were not disclosed. More details...

Stock Symbol: (OTCBB: SKVI)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...